HCPCS Q5119
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (CMS descriptor)
Drugs Drug code Work RVU per service none (2024 fee schedule; adds 0 work RVUs)
Trend
Medicare payment on the code
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2020–2024.
Billers
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2020–2024.
Trend by year: table5 years
| observed | calculated | calculated | calculated | calculated | calculated | reported | |
|---|---|---|---|---|---|---|---|
| 2024 | 133 | $5,663,100 | -65% | 355,143 | 2,130 | 5,472 | 0.00 |
| 2023 | 335 | $16,350,137 | -56% (2023 changed hospital and observation visit codes) | 736,403 | 1,790 | 4,262 | 0.00 |
| 2022 | 415 | $36,822,628 | -23% | 988,908 | 2,010 | 4,818 | 0.00 |
| 2021 | 364 | $47,846,717 | – (Not compared: 2021 changed office visit values) | 951,115 | 2,340 | 4,950 | 0.00 |
| 2020 | 39 | $4,591,121 | first year in data | 79,995 | 1,760 | 3,772 |
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Data years 2020–2024.
By state
Show the table by state3 states
| observed | calculated | calculated | calculated | calculated | calculated | |
|---|---|---|---|---|---|---|
| California | 25 | $1,422,358 | 89,276 | 2,350 | 5,247 | |
| Illinois | 24 | $961,412 | 60,240 | 2,200 | 4,260 | |
| Virginia | 16 | $560,303 | 34,928 | 2,175 | 3,448 |
Not listed: 22 states with fewer than 11 billers (small cells).
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Providers placed by practice address. Data year 2024.
Top metro areas
Show the metro areas1 areas
| observed | calculated | calculated | calculated | calculated | |
|---|---|---|---|---|---|
| Chicago-Naperville-Elgin, IL-IN | 23 | $926,359 | 58,010 | 2,170 |
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). The 1 areas with the most payment among those with at least 11 billers; non-metro parts of each state are one area. Data year 2024.
Specialties billing Q5119 nationally
Hematology-Oncology accounts for 64% of payment for Q5119 nationally in 2024, across 2 specialties on claims.
| observed | calculated | calculated | calculated | calculated | calculated | |
|---|---|---|---|---|---|---|
| Hematology-Oncology | 89 | 67% | $3,628,695 | 64% | 228,259 | 2,565 |
| Rheumatology | 18 | 14% | $1,011,717 | 18% | 63,163 | 3,509 |
Not listed: 8 specialties with fewer than 11 billers (small cells).
Source: CMS Medicare Physician & Other Practitioners public use files (Original Medicare Part B fee-for-service). Provider-level lines (fewer than 11 beneficiaries suppressed by CMS); specialty is the provider type on claims. Data year 2024.
Top billers of Q5119 nationally
Named top billers are a Pro figure, and Pro is not available to buy, so this list is not shown to any account. The counts and totals by state, metro area and specialty on this page are free.
Original Medicare Part B fee-for-service only; CMS suppresses provider lines with fewer than 11 beneficiaries. How these figures are computed · Limitations